In a six-month follow-up study, AstraZeneca’s COVID-19 antibody drug was 83 percent effective in reducing the risk of people contracting symptomatic illness, cementing the drugmaker’s lead in developing preventative coronavirus treatments.

A separate study in patients with mild-to-moderate COVID-19 found that a higher dose of the therapy, AZD7442, reduced the risk of symptoms worsening by 88 percent when given within three days of the onset of symptoms.

The latest round of positive results could position AstraZeneca as a rare supplier of both COVID-19 vaccines and treatments, with the drugmaker previously stating that the therapy’s “real advantage” was as a preventative shot rather than a treatment.

“These new findings add to the growing body of evidence that AZD7442 has the potential to make a significant difference in the prevention and treatment of COVID-19,” said Executive Vice President Mene Pangalos in a statement.